Vera Therapeutics, Inc. 4

Chief Regulatory Officer Nancy Lee Boman received 44,987 RSUs and a stock option for 63,011 shares of Vera Therapeutics Class A Common Stock at $32.23 per share as an inducement equity grant.

On August 3, 2026, Vera Therapeutics, Inc. Chief Regulatory Officer Nancy Lee Boman received an inducement equity package consisting of 44,987 restricted stock units (settling in Class A Common Stock) and a stock option for 63,011 shares at an exercise price of $32.23 per share, all reported as acquisitions on Form 4. The RSUs vest in four equal annual installments on August 20 of 2027, 2028, 2029, and 2030, contingent on continued service, while the option vests 12/48ths on August 3, 2027 and the remaining 36/48ths in equal monthly installments thereafter through full vesting, also subject to continued service. No shares were sold in connection with these grants, and the filings indicate the awards are part of the issuer’s 2024 Inducement Plan, with Boman’s post‑transaction direct ownership reflecting 63,011 shares of Class A Common Stock underlying vested and unvested awards.

Filing Facts

CIK

1831828

Ticker

VERA

Form

4

Source Type

fda

Accession

0002145711-26-000002

Alert Tier

6